![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1681354
¼¼°èÀÇ ¹æ±¤°æ ½ÃÀå ±Ô¸ð ºÐ¼® : Á¦Ç°º°, ¿ëµµº°, ÃÖÁ¾ ¿ëµµº°, À¯Çüº°, Áö¿ªº° ¿¹Ãø(2022-2032³â)Global Cystoscope Market Size Study, by Product, by Application, by End Use, by Type, and Regional Forecasts 2022-2032 |
¼¼°èÀÇ ¹æ±¤°æ ½ÃÀå ±Ô¸ð´Â 2023³â¿¡ ¾à 11¾ï 2,000¸¸ ´Þ·¯·Î, 2024-2032³â¿¡ CAGR 9.99%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ºñ´¢±â°ú ¹× ºÎÀΰú ÁúȯÀÇ À¯º´·ü Áõ°¡, °í·ÉÀÚ Àα¸ÀÇ Áõ°¡, ¹æ±¤°æ ±â±âÀÇ ±â¼ú Áøº¸°¡ ½ÃÀåÀ» ÃËÁøÇÏ´Â ÁÖ¿ä ¿äÀÎÀÔ´Ï´Ù.
Elsevier Inc.°¡ ¹ßÇ¥ÇÑ 2024³â Á¶»ç¿¡ µû¸£¸é ¿©¼ºÀÇ 50-60%°¡ ÀÏ»ý¿¡ ÃÖ¼Ò ÇÑ ¹ø ÀÌ»ó ¿ä·Î°á¼®À» °æÇèÇϰí ÀÖÀ¸¸ç, ¹æ±¤°æ °Ë»ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Å©°Ô Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ WHOÀÇ º¸°í¼(2024³â)¿¡ µû¸£¸é 2030³â±îÁö Àü ¼¼°è Àα¸ÀÇ ¾à 16.66%°¡ 60¼¼ ÀÌ»óÀÌ µÇ¾î Àü¸³¼±ºñ´ëÁõ(BPH), ¹æ±¤°á¼®, ¹æ±¤¾Ï µî ºñ´¢±â°ú ÁúȯÀÇ À¯º´·üÀÌ ³ô¾ÆÁú °ÍÀ¸·Î ÃßÁ¤Çϰí ÀÖ½À´Ï´Ù.
¹æ±¤¾Ï ¹ßº´·ü Áõ°¡µµ ¹æ±¤°æ ½ÃÀåÀÇ ÁÖ¿ä ¼ºÀå ¿äÀÎÀÔ´Ï´Ù. ±¹Á¦¾Ï¿¬±¸¼Ò(2022)´Â Àü ¼¼°è¿¡¼ 60¸¸ ¸í ÀÌ»óÀÌ ¹æ±¤¾ÏÀ¸·Î Áø´Ü¹Þ°í 22¸¸ ¸í ÀÌ»óÀÌ »ç¸ÁÇÑ °ÍÀ¸·Î º¸°íÇϰí ÀÖ½À´Ï´Ù. ¹æ±¤°æ °Ë»ç´Â ¹æ±¤¾ÏÀÇ ÁÖ¿ä Áø´Ü ÅøÀ̱⠶§¹®¿¡ Áúº´ ºÎ´ã Áõ°¡´Â ¿¹Ãø ±â°£ Áß ½ÃÀå ¼ö¿ä¸¦ ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
±â¼ú Çõ½ÅÀº ¹æ±¤°æ °Ë»ç ÀýÂ÷¸¦ º¯È½Ã۰í ȯÀÚÀÇ Æí¾ÈÇÔ°ú Áø´Ü Á¤È®µµ¸¦ Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î UroViu Corp´Â 2023³â 4¿ù Uro-GHD¸¦ ¹ßÇ¥Çß½À´Ï´Ù. ÀÌ Á¦Ç°Àº À¯¿¬¼ºÀ» ³ôÀ̰í ȯÀÚÀÇ Æí¾ÈÇÔÀ» Çâ»ó½Ã۱â À§ÇØ ¼³°èµÈ ÀÏȸ¿ë ¹«±Õ ¹æ±¤°æÀÔ´Ï´Ù. ¶ÇÇÑ 2021³â aScope 4 CystoÀÇ FDA ½ÂÀÎÀ» ȹµæÇÏ¿© ºñµð¿À ¹æ±¤°æ ¼Ö·ç¼ÇÀÇ °¡¿ë¼ºÀ» È®´ëÇß½À´Ï´Ù. °¨¿° °ü¸® ¹®Á¦·Î ÀÎÇØ ÀÏȸ¿ë ¹æ±¤°æ äÅÃÀÌ Áõ°¡Çϰí ÀÖÀ¸¸ç, ±³Â÷ ¿À¿° ¹× ÀÇ·á °ü·Ã °¨¿°(HAI)ÀÇ À§ÇèÀ» °¨¼Ò½Ã۰í ÀÖ½À´Ï´Ù.
Áö¿ªº°·Î´Â ºÏ¹Ì°¡ 2023³â °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. À̴ ÷´Ü ÀÇ·á ÀÎÇÁ¶ó, ¹æ±¤¾Ï ¹ßº´·ü Áõ°¡, Olympus Corporation, Boston Scientific Corporation, Ambu Inc.¿Í °°Àº ÁÖ¿ä ½ÃÀå ±â¾÷ÀÇ °·ÂÇÑ ÀÔÁö¿¡ ÈûÀÔÀº °ÍÀÔ´Ï´Ù. ÇÑÆí, ¾Æ½Ã¾ÆÅÂÆò¾çÀº ÀÇ·á ÅõÀÚ Áõ°¡, ºñ´¢±â°ú Áúȯ¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, Áß±¹, Àεµ, ÀϺ» µîÀÇ ±¹°¡¿¡¼ Áø´Ü ½Ã¼³¿¡ ´ëÇÑ Á¢±Ù¼º È®´ë¿¡ ÈûÀÔ¾î °¡Àå ºü¸¥ ¼ºÀåÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
The global cystoscope market was valued at approximately USD 1.12 billion in 2023 and is projected to grow at a CAGR of 9.99% from 2024 to 2032. The increasing prevalence of urological and gynecological disorders, a growing geriatric population, and technological advancements in cystoscope devices are key factors driving the market.
Cystoscopes are widely used for the diagnosis and treatment of urinary tract disorders, bladder cancer, urinary incontinence, and urinary tract infections (UTIs). According to a 2024 study published by Elsevier Inc., 50%-60% of women experience at least one UTI in their lifetime, significantly increasing the demand for cystoscopic procedures. Additionally, a WHO report (2024) estimates that by 2030, around 16.66% of the global population will be aged 60 or older, contributing to a higher prevalence of urological conditions such as benign prostatic hyperplasia (BPH), bladder stones, and bladder cancer.
The rising incidence of bladder cancer is also a major growth driver for the cystoscope market. The International Agency for Research on Cancer (2022) reported that over 600,000 people worldwide were diagnosed with bladder cancer, leading to more than 220,000 deaths. Since cystoscopy is the primary diagnostic tool for bladder cancer, the increasing disease burden is expected to propel market demand over the forecast period.
Technological innovations are transforming cystoscopy procedures, improving patient comfort and diagnostic accuracy. For instance, UroViu Corp introduced the Uro-GHD in April 2023, a single-use, sterile cystoscope designed for enhanced flexibility and improved patient comfort. Additionally, Ambu Inc. received FDA approval for the aScope 4 Cysto in 2021, expanding the availability of video cystoscopy solutions. The adoption of single-use cystoscopes is rising due to infection control concerns, reducing the risk of cross-contamination and healthcare-associated infections (HAIs).
From a regional perspective, North America held the largest market share in 2023, driven by advanced healthcare infrastructure, increasing incidence of bladder cancer, and strong presence of key market players such as Olympus Corporation, Boston Scientific Corporation, and Ambu Inc.. Meanwhile, the Asia Pacific region is projected to witness the fastest growth, fueled by rising healthcare investments, increasing awareness of urological disorders, and expanding access to diagnostic facilities in countries such as China, India, and Japan.